{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:14:34Z","timestamp":1785453274699,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clinthera.2021.07.008","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T12:29:32Z","timestamp":1628252972000},"page":"e264-e273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers"],"prefix":"10.1016","volume":"43","author":[{"given":"Zhen-dong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-ying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-fang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.07.008_bib0001","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0002","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0003","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172845","article-title":"Suitability of APINCH high-risk medications use in diabetes mellitus","volume":"867","author":"Zafar","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0005","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.ajkd.2018.03.022","article-title":"SGLT2 Inhibition for the prevention and treatment of diabetic kidney disease: a review","volume":"72","author":"Alicic","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0007","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/14656566.2018.1525360","article-title":"Ertugliflozin as a monotherapy for the treatment of type 2 diabetes","volume":"19","author":"Hu","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0008","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40261-015-0366-7","article-title":"Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus","volume":"36","author":"Yong","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.clinthera.2020.12.012","article-title":"Tolerability, pharmacokinetic, and pharmacodynamic profiles of henagliflozin, a novel selective inhibitor of sodium-glucose cotransporter 2, in healthy subjects following single- and multiple-dose administration","volume":"43","author":"Zhang","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113632","article-title":"Characterization and quantitative determination of henagliflozin metabolites in humans","volume":"192","author":"Chen","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0012","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40261-015-0312-8","article-title":"Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin","volume":"35","author":"Reuter","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0013","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.clinthera.2020.10.002","article-title":"Effect of food on the pharmacokinetic and pharmacodynamic profiles of hetrombopag in healthy volunteers","volume":"42","author":"Wang","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0014","series-title":"Technical Guidelines for the Study of Bioavailability and Bioequivalence of Chemical Pharmaceutical Products","year":"2015"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1124\/dmd.112.049551","article-title":"Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects","volume":"41","author":"Miao","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0016","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.14314","article-title":"Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Lu","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0017","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1463-1326.2011.01397.x","article-title":"Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0018","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijpharm.2016.07.017","article-title":"Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets","volume":"511","author":"LaCreta","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2021.07.008_bib0019","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5414\/CP203343","article-title":"A PK\/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects","volume":"57","author":"Dawra","year":"2019","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:51Z","timestamp":1758963411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0149291821002526"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.07.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}